REG - Polarean Imaging PLC - Appointment of Chief Medical Advisor

Polarean ImagingAnnouncement

28/08/2024 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240828:nRSb8706Ba&default-theme=true

RNS Number : 8706B  Polarean Imaging PLC  28 August 2024

28 August
2024

 

Polarean Imaging plc

("Polarean" or the "Company")

 

Appointment of Chase Hall, M.D., as Chief Medical Advisor

Adds significant pulmonary expertise to help drive engagement with the medical
community

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that
it has appointed Chase Hall, M.D., as Chief Medical Advisor.

 

Dr. Hall is an Associate Professor, Pulmonary, Critical Care and Sleep
Medicine, at the University of Kansas Medical Center in the Division of
Pulmonary and Critical Care. He also serves as Associate Director at the
University of Kansas Interstitial Lung Disease and Rare Lung Disease Clinic.
Dr. Hall's research focus has been on establishing imaging biomarkers in
respiratory disease, utilising Xenon MRI. In his lab, he is currently working
to utilise Xenon MRI as a sensitive measure of treatment response in a number
of respiratory diseases, as well as rapid image acquisition protocols and
fully automated image analysis programmes. In addition, Dr. Hall is a member
of the Xenon MRI Clinical Trials Consortium, a growing collaboration of 13
clinical research sites; its activities include the harmonisation and
standardisation of Xenon imaging protocols for multi-center clinical trials,
training of new sites establishing Xenon MRI programmes, and growing awareness
and expertise in the field.

 

In his role as Chief Medical Advisor, Dr. Hall will assist in guiding
Polarean's clinical development strategy and medical education initiatives
with fellow clinicians and professional societies. He will leverage his
experience while maintaining his clinical pulmonology practice, providing
valuable insights to help Polarean address unmet medical needs in pulmonary
care.

 

Dr. Hall received his medical degree from the University of Kansas School of
Medicine and completed his residency in Internal Medicine and fellowship
training in Pulmonary and Critical Care at Washington University School of
Medicine in St. Louis. He serves as a peer-reviewer for many prestigious
journals, such as Academic Radiology and The American Journal of Respiratory
and Critical Care Medicine.

 

Christopher von Jako, Ph.D, CEO of Polarean, said: "I am delighted to welcome
Dr. Hall to Polarean as our new Chief Medical Advisor. As a leading expert in
pulmonary medicine as well as a champion of our Xenon MRI technology platform,
Dr. Hall is a perfect fit for the Company. His appointment represents a
significant step in growing the Polarean team as we look to expand Xenon MRI
to more clinical and research sites."

 

Chase Hall, M.D., CMA of Polarean, said: "For several years, I have been
deeply interested in the potential of Xenon MRI to assist pulmonary clinicians
and the patients we treat. There is a significant unmet need in pulmonary
medicine for imaging technology that can better characterise disease, monitor
response to therapy, and guide interventional procedures. I am excited to join
Polarean to help guide the clinical development and implementation of this
unique technology in pulmonary medicine."

 

Enquiries:

 

 Polarean Imaging plc                                        www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D, Chief Executive Officer         Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                             +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Phillip Marriage          Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

About Polarean

 

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

 

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 12 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.XENOVIEW.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBUGDIXBDDGSR